Bioheart Personal Heart Monitor-Provides Information on User’s Heart Performance

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

January 11, 2021

Bioheart, a personal heart monitor by Biotricity, Inc. is designed for individuals diagnosed with or at risk for cardiovascular disease.

Bioheart continuously monitors daily activities, and provides critical information on the user’s heart performance, empowering patients to understand better and manage their heart conditions.

Bioheart availability is targeted for Q3 2021. Biotricity will showcase Bioheart at Pepcom’s Digital Experience during CES 2021 on January 11, 2021. For an advance look at Bioheart, watch this video.

Bioheart is a natural extension to Biotricity’s cardiac diagnostic offering. Today, there is no solution for personal lifestyle management in cardiac diagnostics. Bioheart will fill this gap while enhancing awareness for patients so they can visit their physician and receive a proper diagnosis.

“Cardiovascular disease is the number one killer in the US. Millions of cardiac patients are living with cardiac disease with no insight into their condition,” said Dr. Waqaas Al-Siddiq, founder & CEO, Biotricity Inc. “Bioheart will help cardiac patients to take control of their condition and improve their quality of life.”

Key features of Bioheart include:

  • Dry Lead Technology – Bioheart is one of the only wearable devices that continuously collects ECG (heart) data through dry lead electrodes.
  • Provides Critical Information – Bioheart monitors heart health, respiration, physical activity, and calorie burn in a user-friendly format.
  • Ergonomic Design – Bioheart is designed to maximize patient comfort during regular day-to-day activities through its adjustable chest band.
  • Three-Channel Recording – Bioheart is one of the only consumer wearable that can provide continuous three-channel recording of ECG data. All other known consumer devices are one-channel and lack continuous recording capability.
  • Extended Battery Life – The device can be worn continuously for 48 hours before requiring a one-hour charge, enabling long term continuous data collection.
  • Complementing Data – Individuals can gain further insights by sharing their Bioheart data with health care professionals for lifestyle management.
  • Proven Technology – Bioheart uses the same core ECG technology used in the FDA-cleared Bioflux to diagnose patients.

“We are very excited about the addition of the Bioheart personal heart monitor to our product portfolio and believe it will complement our existing and future product offerings.”, added Dr. Waqaas Al Siddiq. FAQ can be found here.



Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.